From: Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis
Study (Phase, ID) | Study centres(No) | Sample size (No); median age | Sex (male/female,%) | Study objective | Virus species | Group Intervention (arm 1/arm 2/arm 3/arm 4) |
---|---|---|---|---|---|---|
Moehler et al. [13] (II, NCT01387555) | 38 | 86/43;NG | 81.4/18.6 | Advanced hepatocellular carcinoma | Vaccinia | Pexa-Vec 1 * 109 pfu/best supportive care |
Noonan et al. [14] (II, NCT01280058) | 6 | 36/37;64 | 56.2/43.8 | Recurrent or metastatic pancreatic cancer | Reovirus | Pelareorep 3 * 1010 TCID 50 plus paclitaxel or carboplatin/paclitaxel or carboplatin |
Gedeon et al. [15] (II, NCT01199263) | 36 | 54/54;NG | 0/100.0 | Recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer | Reovirus | Paclitaxel/p pelareorep 3 * 1010 TCID 50 plus paclitaxel |
Heo et al. [16] (II, NCT00554372) | 9 | 14/16;64.9 | 76.7/23.3 | Unresectable primary hepatocellular carcinoma | Vaccinia | Pexa-Vec 1 * 108 pfu/Pexa-Vec 1 * 109 pfu |
Bernstein et al. [17] (II, NCT01656538) | 7 | 36/38;NG | 0/100.0 | Metastatic breast cancer | Reovirus | Pelareorep 3 * 1010 TCID 50 plus paclitaxel/paclitaxel |
Bradbury et al. [18] (II, NCT01708993) | 12 | 38/37/39/38;NG | 50.7/49.3 | Advanced or metastatic non-small-cell lung cancer | Reovirus | Pelareorep 4.5 * 1010 TCID 50 plus pemetrexed/pemetrexed/pelareorep 4.5 * 1010 TCID 50 plus docetaxel/docetaxel |
Chesney et al. [19] (II, NCT01740297) | 40 | 98/100;NG | 57.6/42.4 | Advanced unresectable melanoma | Herpes simplex | T-VEC 1 * 106 pfu/1 * 108 pfu plus ipilimumab/ipilimumab |
Eigl et al. [20] (II, NCT01619813) | 11 | 41/44; 69 | NG | Metastatic castration resistant prostate cancer | Reovirus | Pelareorep 3 * 1010 TCID 50 plus docetaxel/docetaxel |
Jonker et al. [21] (II, NCT01622543) | 10 | 51/52;60 | 61.2/38.8 | Metastatic colorectal cancer | Reovirus | Pelareorep 3 * 1010 TCID 50 plus FOLFOX6 or bevacizumab/FOLFOX6 or bevacizumab |
Andtbacka et al. [22] (III, NCT00769704) | 83 | 295/141;63.1 | 57.2/42.8 | Unresectable melanoma | Herpes simplex | T-VEC 1 * 106 pfu/1 * 108 pfu/GM-CSF 125 μg/m2/day |
Schenk et al. [23] (II, NCT01017601) | 196 | 26/24;63 | 48.0/52.0 | Extensive-stage small cell lung cancer | Seneca valley virus | NTX-010 1 * 1011 (viral particles/kg)/placebo |
PHOCUS [24] (III, NCT02562755) | 142 | 234/225;60.9 | 84.1/15.9 | Advanced hepatocellular carcinoma | Vaccinia | Pexa-Vec 1 * 109 pfu plus sorafenib/sorafenib |
Burke et al. [25] (II, NCT01394939) | 11 | 25/17;58.9 | 40.0/60.0 | Metastatic, refractory colorectal carcinoma | Vaccinia | Pexa-Vec 1 * 109 pfu/Pexa-Vec 1 * 109 pfu plus irinotecan |